ASCO 2010 ALGORITHM - ESAs FOR CHEMOTHERAPY-INDUCED ANEMIA



Please note

The US Food and Drug Administration (FDA) approved labels (dated 2/16/2010) for ESAs state, in part:

ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see labeled warnings).

- To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusion.
- Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense Aranesp® to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.
- Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.
- ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.
- Discontinue following the completion of a chemotherapy course.

Source: www.fda.gov

This flow sheet is derived from recommendations in the ASCO/ASH Clinical Practice Guideline Update on the Use Of Epoetin And Darbepoetin in Adult Patients With Cancer. This flow sheet is a practice tool based on ASCO® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this flow sheet are voluntary. The practice guidelines and additional information are available at http://www.asco.org/guidelines/esa.